Olema Oncology Reports Incentive Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema OncologyOlema Oncology

Olema Oncology

SAN FRANCISCO, May 2, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers today announced that the company has granted stock options to six new employees to purchase an aggregate of 187,400 shares of the Company’s common stock, effective May 1, 2024. These awards have been approved by the Compensation Committee of Olema’s Board of Directors. Directors and awarded under the Company’s 2022 Inducement Plan, with a grant date of May 1, 2024, as incentive material for new employees joining Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over a four-year period, with 25 percent vesting on the first anniversary of such employee’s vesting start date and the remainder vesting in 36 equal monthly installments over the next three years, provided the employee is continuously employed by Olema from such vesting dates. The stock options have a term of 10 years and an exercise price of $10.40 per share, equal to the last reported sales price of the Company’s common stock as reported by Nasdaq on May 1, 2024. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Incentive Plan.

Olema provides this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine cancers, nuclear receptors and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally available full estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco with offices in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.

Geoffrey Mogilner, Vice President of Investor Relations and Communications
[email protected]